Clincosm LogoSign in Get a demo

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Sponsor
University of Maryland, Baltimore (Other)
Overall Status
Recruiting
CT.gov ID
NCT04098081
Collaborator
(none)
58
Enrollment
1
Location
2
Arms
72.6
Anticipated Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of galeterone, an investigational drug, in pancreatic cancer.

The FDA (the U.S. Food and Drug Administration) has not approved galeterone for pancreatic cancer. Galeterone is an androgen receptor inhibitor that showed anti-cancer activity in pancreatic cancer in research lab. In this study, the investigator is interested in evaluating galeterone alone or in combination with chemotherapy in treating pancreatic cancer.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
58 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
2 parallel arm phase II study of galeterone alone or galeterone with gemcitabine in advanced pancreatic cancer2 parallel arm phase II study of galeterone alone or galeterone with gemcitabine in advanced pancreatic cancer
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy
Actual Study Start Date :
Dec 12, 2019
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: galeterone

galeterone orally once daily

Drug: galeterone
Therapeutic
Experimental: galeterone+gemcitabine

daily dose galeterone and weekly dose of gemcitabine

Drug: galeterone
Therapeutic

Drug: Gemcitabine
Therapeutic

Outcome Measures

Primary Outcome Measures

  1. response rate [8 weeks post treatment]

    number of patients whose disease shrink during treatment

Secondary Outcome Measures

  1. progression-free survival [From date of randomization until the date of first documented progression, assessed up to 100 months]

    time for galeterone to control the disease

  2. overall survival [From date of randomization until the date of death from any cause, assessed up to 100 months]

    total life expectancy

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Ability to understand and willingness to sign a written informed consent document

  2. Agree to comply with the study requirements and agrees to come to the clinic/hospital for required study visits

  3. 18 years of age or order

  4. Histologic or cytologic diagnosis of pancreatic adenocarcinoma

  5. Measurable metastatic disease documented by CT/MRI at least 1cm in greatest dimension

  6. Have received 2 lines of prior systemic therapy; those patients must demonstrate continued disease progression (RECIST 1.1) and must not have received chemotherapy for at least 4 weeks prior to trial assignment;

  7. ECOG performance status must be 0-2 (Appendix A).

  8. All participants (male and female) with reproductive potential must practice an effective method of contraception while on this study in order to minimize risks to fetuses.

  9. Men and women of all ethnic groups are eligible for this trial.

  10. Able to swallow up to six pills and retain oral medication

  11. Expected life expectancy of more than 12 weeks.

  12. Patient has adequate bone marrow function as demonstrated by the following blood

  • counts at Baseline (obtained ≤14 days prior to randomization):

  • Absolute neutrophil count (ANC) ≥1.5 × 109/L;

  • Platelet count ≥100,000/mm3 (100 × 109/L);

  • Hemoglobin (Hgb) ≥ 8 g/dL.

  1. Patient has adequate organ functions at baseline (obtained ≤14 days prior to randomization):

  • AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal range (ULN),

  • Total bilirubin ≤ 1.2mg/dl

  • Serum creatinine within normal limits or calculated clearance ≥50 mL/min. If using creatinine clearance, actual body weight should be used for calculating creatinine clearance (eg, using the Cockroft-Gault formula). For patients with a Body Mass Index (BMI) >30 kg/m2, adjusted body weight should be used instead.

  1. Patients with well controlled oligo brain metastasis are eligible Ability to understand and willingness to sign a written informed consent document.

  2. Agree to comply with the study requirements and agrees to come to the clinic/hospital for required study visits.

  3. 18 years of age or order.

  4. Histologic or cytologic diagnosis of stage IV pancreatic adenocarcinoma.

  5. Measurable disease per RECIST 1.1 criteria.

  6. Have received 2 lines of prior systemic therapy; those patients must demonstrate continued disease progression (RECIST 1.1) and must not have received chemotherapy for at least 4 weeks prior to trial assignment.

  7. ECOG performance status must be 0-2 (Appendix A).

  8. All participants (male and female) with reproductive potential must agree to be abstinent or practice an effective method of contraception while on this study in order to minimize risks to fetuses.

  9. Men and women of all ethnic groups are eligible for this trial.

  10. Able to swallow up to six pills and retain oral medication.

  11. Expected life expectancy of more than 12 weeks.

Exclusion Criteria:

  1. Participation in another clinical trial involving experimental therapy for pancreatic adenocarcinoma within 4 weeks prior to enrollment or simultaneous participation in a study involving investigational treatment.

  2. Prior anti-cancer therapy:

  • Prior treatment with galeterone, or anti-androgens.

  • Prior radiation therapy within 4 weeks (if single fraction of radiotherapy within 2 weeks).

  1. Concurrent use of other anti-cancer agents.

  2. Major surgery within 4 weeks prior to randomization.

  3. The following medical conditions:

  • New York Heart Association Class III or IV congestive heart failure.

  • Myocardial infarction/unstable angina (within the 6 months prior to randomization).

  • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia).

  • History of long QT syndrome, Mobitz II second or third degree heart block without a permanent pacemaker in place.

  • Bradycardia as defined by heart rate of <50 beats/minute at Screening ECG.

  • History of chronic or active Hepatitis B or Hepatitis C or other known chronic liver disease. Patients recovered from hepatitis are not excluded from the study.

  • Known human immunodeficiency virus (HIV) infection.

  • Uncontrolled hypertension (defined as systolic blood pressure > 170 mmHg or diastolic blood pressure of > 105 mmHg measured on at least two occasions, two weeks apart) despite acceptable anti-hypertension therapy.

  • Hypotension (defined as systolic blood pressure <90 mmHg).

  • History of adrenal insufficiency or hyperaldosteronism.

  • Gastrointestinal disorders or gastric bypass surgery, with the exception of pancreatic cancer and its complications, including lap bands that could interfere with the absorption of galeterone.

  • Serious active infections requiring systemic treatment or nonmalignant medical illnesses that are uncontrolled.

  • History of seizure or any condition or concomitant use of any medication that may predispose to seizure or lower the seizure threshold.

  • History of loss of consciousness or transient ischemic attack within 12 months of randomization.

  • History of (in the past 5 years) other malignancy, other than curatively treated nonmelanomatous skin cancer and superficial transitional cell carcinoma of the bladder.

  • Cranial/spinal epidural disease.

  • The patient has known allergy to any of the treatment components.

  1. Any physical or mental condition or social situation that, in the opinion of the Investigator, may interfere with the patient's ability to comply with the trial procedures, confound the ability to interpret data from the study or places the patient at unacceptable risk if he participates in this study.

  2. Current alcohol abuse or illicit drug use.

  3. Since the teratogenic potential of this combination is currently unknown, females who are pregnant or lactating are excluded.

  4. Females at reproductive age must have a negative urine pregnancy test prior to entry to this study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Maryland Medical Center Baltimore Maryland United States 21201

Sponsors and Collaborators

  • University of Maryland, Baltimore

Investigators

  • Principal Investigator: Aaron Ciner, MD, University of Maryland, Baltimore

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of Maryland, Baltimore
ClinicalTrials.gov Identifier:
NCT04098081
Other Study ID Numbers:
  • 1911GCCC
First Posted:
Sep 20, 2019
Last Update Posted:
Mar 11, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Maryland, Baltimore
pancreatic cancer
Additional relevant MeSH terms:
Adenocarcinoma
Pancreatic Neoplasms
Gemcitabine
3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene

Study Results

No Results Posted as of Mar 11, 2022